A nationwide population-based study of patients on dialysis uncovers an alarming rate of prescribing errors.
Enoxaparin is contraindicated — and eptifibatide is not recommended — in patients undergoing dialysis. Both drugs are excreted by the kidneys and associated with an increased risk for bleeding complications in these patients. Moreover, antithrombotic alternatives that are not excreted by the kidneys are available for both drugs. Investigators used data from the National Cardiovascular Data Registry's CathPCI registry to determine the use of these two antithrombotics in 22,778 dialysis patients undergoing percutaneous coronary intervention (mean age, 64).
Overall, 22.3% of the study cohort received an inappropriate antithrombotic; of these patients, 47% received enoxaparin, 64% received eptifibatide, and 11% received both drugs. In a multivar…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association